CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, is excited to announce the pricing of a public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share.
This offering will bring in gross proceeds of $5,000,000 before underwriting discounts and offering expenses. All of the shares are being offered by the Company, with a closing expected on July 20, 2023, subject to customary closing conditions.
The Company seeks to leverage the proceeds from this offering to further the development of Multikine and bolster its corporate initiatives. This investment will enable the Company to make strides towards improving the quality of life for individuals affected by the diseases that Multikine targets.
ThinkEquity is proud to serve as the sole book-running manager for this exciting offering. We are thrilled to be part of such a significant step forward for the investors involved.
About CEL-SCI Corporation
CEL-SCI is a pioneering biotechnology company with a mission to activate the immune system, allowing it to tackle cancer and infectious diseases. Its current leading therapy, Multikine, has been granted Orphan Drug Status by the FDA after a successful Phase 3 clinical trial with head and neck cancer patients. CEL-SCI has grown to expand the operations of its research with offices in Vienna, Virginia and near Baltimore, Maryland.